Mar 24, 2025
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
Mar 19, 2025
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Jan 30, 2025
Immutep Quarterly Activities Report Q2 FY25
Jan 21, 2025
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Jan 06, 2025
Patient Enrolment Completed for INSIGHT-003
Dec 16, 2024
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Dec 15, 2024
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Dec 11, 2024
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
Dec 09, 2024
Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
Nov 14, 2024
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
Oct 28, 2024
Immutep Quarterly Activities Report Q1 FY25
